⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 27, 2026Journal of Clinical Oncology

Time on treatment for systemic therapies for patients with hormone receptor-positive breast cancer and BRCA1 , BRCA2 , or PALB2 pathogenic variants.

Gerneiva Parkinson Shayan S. Nazari Maryam B. Lustberg Andrew Elliott George W. Sledge Alvaro Alvarez Soto Jennifer L. Caswell‐Jin Allison W. Kurian Stephanie L. Graff

View at Publisher

Ask AI

Bookmark

Share

Key Points

The study aims to compare time on treatment for patients with hormone receptor-positive breast cancer with and without BRCA pathogenic variants.
Somatic DNA and RNA sequencing on tumors was performed.
Time on treatment was calculated from first to last treatment based on insurance claims.
Cox-proportional hazard analyses assessed time on treatment between patients with BRCA pathogenic variants and wild-type BRCA.
Patients with mBRCA had shorter time on treatment for aromatase inhibitors (21.7 vs 25.8 months; HR=1.16, 95% CI 1.04-1.29, p=0.009).
PET patients had longer time on treatment with PARPi compared to wtBRCA (5.8 vs 2.1 months; HR=0.51, 95% CI 0.36-0.73, p<0.001).
High tumor mutational burden patients had shorter time overall for most treatments compared to low tumor mutational burden, except for aromatase inhibitors.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Compares time on treatment for hormonal therapies in patients with BRCA mutations, suggesting distinct outcomes.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Parkinson et al. (2026) studied this question.

synapsesocial.com/papers/6a192ed7fab5b468c441819e https://doi.org/10.1200/jco.2026.44.16_suppl.1096

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Use of transcriptomic signatures of <i>RAD51</i> and <i>GATA6</i> to predict real-world overall survival with platinum therapy in <i>BRCA/PALB2</i> wild-type metastatic pancreatic cancer.Original Research · 2026
2Abstract PO2-17-06: Real world treatment patterns and clinical outcomes by germline BRCA (gBRCA) mutation status in patients with HER2-negative early breast cancer in the US community oncology setting: a retrospective observational chart-review study2024
3Evaluation of biomarkers of response in patients with breast cancer with <i>BRCA</i> 1/2 pathogenic variants treated with PARP inhibitors.2024
4Real-world tumor BRCA testing patterns and PARP inhibitor use in HER2-negative metastatic breast cancer.2024 · 3 citations
5Abstract PS2-02-08: Real-world PARP inhibitor use and clinical outcomes in US patients with HER2-negative metastatic breast cancerHuman Clinical Trial · 2026

More related papers

Abstract PS2-02-07: Impact of BRCA homozygous copy loss on clinical outcomes of patients (pts) with metastatic breast cancer (MBC) treated with PARP inhibitors (PARPi)2026
Beyond <i>BRCA</i> : Real-world outcomes with poly(ADP-ribose) polymerase inhibitors among patients with metastatic castration-resistant prostate cancer and homologous recombination repair mutations.2026
64P Response to PARPi in advanced high-grade serous ovarian cancer (HGSOC) based on the location and type of BRCA mutation: Real-world data from a Spanish tertiary university hospital2024

More from Journal of Clinical Oncology

COMPANION-002: A Randomized Phase 2/3 Trial of Tovecimig Plus Paclitaxel versus Paclitaxel Alone as a Second-line Therapy in Patients with Advanced Biliary Tract CancerSat,
Phase II Study of Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous Cell Carcinoma: Final AnalysisSat,